title: Prediction error, ketamine and psychosis: An updated model.
abstract: In 2007, we proposed an explanation of delusion formation as aberrant prediction error-driven associative learning. Further, we argued that the NMDA receptor antagonist ketamine provided a good model for this process. Subsequently, we validated the model in patients with psychosis, relating aberrant prediction error signals to delusion severity. During the ensuing period, we have developed these ideas, drawing on the simple principle that brains build a model of the world and refine it by minimising prediction errors, as well as using it to guide perceptual inferences. While previously we focused on the prediction error signal per se, an updated view takes into account its precision, as well as the precision of prior expectations. With this expanded perspective, we see several possible routes to psychotic symptoms - which may explain the heterogeneity of psychotic illness, as well as the fact that other drugs, with different pharmacological actions, can produce psychotomimetic effects. In this article, we review the basic principles of this model and highlight specific ways in which prediction errors can be perturbed, in particular considering the reliability and uncertainty of predictions. The expanded model explains hallucinations as perturbations of the uncertainty mediated balance between expectation and prediction error. Here, expectations dominate and create perceptions by suppressing or ignoring actual inputs. Negative symptoms may arise due to poor reliability of predictions in service of action. By mapping from biology to belief and perception, the account proffers new explanations of psychosis. However, challenges remain. We attempt to address some of these concerns and suggest future directions, incorporating other symptoms into the model, building towards better understanding of psychosis.
authors.affiliation: Department of Psychiatry, Yale University, New Haven, CT, USA.
authors.forename: Philip R
authors.initials: PR
authors.lastname: Corlett
authors.affiliation: Roche Switzerland, Basel, Switzerland.
authors.forename: Garry D
authors.initials: GD
authors.lastname: Honey
authors.affiliation: Department of Psychiatry, University of Cambridge, Cambridge, UK philip.corlett@yale.edu.|Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
authors.forename: Paul C
authors.initials: PC
authors.lastname: Fletcher
mesh_terms: D000818:Animals; D001245:Association Learning / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D003702:Delusions / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D006212:Hallucinations / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007649:Ketamine / Q000009:adverse effects*; D011605:Psychoses, Substance-Induced / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D015203:Reproducibility of Results
chemical_list: D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine
keywords: Drug model; computational psychiatry; delusions; hallucinations; ketamine; psychosis; schizophrenia